Abstract
Shock waves are one of the most efficient mechanisms of energy dissipation observed in nature. In this study, utilizing the instantaneous mechanical impulse generated behind a micro-shock wave during a controlled explosion, a novel nonintrusive needleless vaccine delivery system has been developed. It is well-known that antigens in the epidermis are efficiently presented by resident Langerhans cells, eliciting the requisite immune response, making them a good target for vaccine delivery. Unfortunately, needle-free devices for epidermal delivery have inherent problems from the perspective of the safety and comfort of the patient. The penetration depth of less than 100 μm in the skin can elicit higher immune response without any pain. Here we show the efficient utilization of our needleless device (that uses micro-shock waves) for vaccination. The production of liquid jet was confirmed by high-speed microscopy, and the penetration in acrylamide gel and mouse skin was observed by confocal microscopy. Salmonella enterica serovar Typhimurium vaccine strain pmrG-HM-D (DV-STM-07) was delivered using our device in the murine salmonellosis model, and the effectiveness of the delivery system for vaccination was compared with other routes of vaccination. Vaccination using our device elicits better protection and an IgG response even at a lower vaccine dose (10-fold less) compared to other routes of vaccination. We anticipate that our novel method can be utilized for effective, cheap, and safe vaccination in the near future.
INTRODUCTION
Shock waves appear in nature whenever the different elements in a fluid approach one another with a velocity faster than the local speed of sound (8). Shock waves are essentially nonlinear waves that propagate at supersonic speeds. Such disturbances occur in steady transonic or supersonic flows during explosions, earthquakes, tsunamis, lightning strikes, and contact surfaces in laboratory devices. Any sudden release of energy (within a few microseconds) will invariably result in the formation of a shock wave, since it is one of the efficient mechanisms of energy dissipation observed in nature. The dissipation of mechanical, nuclear, chemical, and electrical energy in a limited space will result in the formation of a shock wave. However, it is possible to generate micro-shock waves in the laboratory by different methods, including controlled explosions. One of the unique features of shock wave propagation in any medium (solid, liquid, or gases) is their ability to instantaneously increase the pressure and temperature of the medium. Researchers are exploiting this behavior of shock waves to develop novel experimental tools/technologies that transcend the traditional boundaries of basic science and engineering (11). Shock waves have been used successfully for disintegrating kidney stones (16), noninvasive angiogenic therapy (10), and osteoporosis treatment (29). In the present study, we have generated a novel method to produce micro-shock waves using microexplosions. Further utilizing the impulse behind such microblasts, we have developed a novel needleless device for delivering drugs and vaccines into biological systems in a nonintrusive fashion (G. Jagadeesh, 2009, U.S. patent application 12480514).
Drug delivery plays a pivotal role in the field of human health care where nearly 12 billion injections are administered annually for medical purposes, 3% of which are used for immunization (21). Throughout the world, 0.7% of deaths and 0.6% of disability-adjusted life years (DALYs) are caused by contaminated injections in health care settings (17). In low- and middle-income countries, the possibility of HIV transmission through contaminated injections is high (14, 25). Each year, unsafe injections cause an estimated 1.3 million early deaths, loss of 26 million years of life, and an annual burden of $535 million (U.S. dollars) in direct medical expenses. In four out of six parts of the world, more than 30% of the immunization injections are unsafe per the WHO estimation (20). Apart from the unsafe injections, needle injuries, accidental needle sticks, needle phobia, and possible side effects due to transiently high plasma drug concentration are very common (2). A needle-free delivery system that can deliver the drug either actively or passively is a rational alternative. In the case of delivering the drug actively, a driving force is necessary for the transport of drug across the skin, which may be accomplished using jet injectors, electroporation, iontophoresis, ultrasound, powder injection, and tape stripping (2). Different delivery systems have been developed to deliver vaccine to the epidermal layer of skin (4, 28). Recently, a novel polymer-based microneedle technology has been developed for vaccination (28), and the existing microneedle technology has also been checked for intradermal delivery of vaccine (1, 27). However, the available needleless delivery systems have their own limitations, such as cost, cross contamination, pain, and bleeding (21). In this study, we have demonstrated efficient vaccination in a murine model using our novel needleless device.
MATERIALS AND METHODS
Development of a needle-free delivery device.
A simple and novel methodology to generate micro-blast waves in a repeatable fashion and in a controlled manner using a small amount of explosives was developed. A simple prototype model was developed to transfer the energy of micro-blast waves to the liquid. The delivery device consists of an ignition system, a polymer tube coated with explosive material, metal foil, drug-holding chamber, and cavity holder (Fig. 1D).
Time-resolved schlieren technique.
A high-speed digital camera, Phantom 7.1 (Vision Research Inc.), that is capable of recording 6,688 frames per second at a resolution of 800 by 600 pixels using a self-resetting complementary metal oxide semiconductor (SR-CMOS) imaging array is used for this experiment. The schlieren images were recorded by operating the camera at a speed of 10,000 frames per second with a resolution of 450 by 450 pixels and an exposure time of 3 μs. A 300-W, continuous halogen light source is used in these experiments, and the operation of the camera is synchronized with the polymer tube firing operation using a trigger pulse generated by the pressure sensor located at the open end of the polymer tube.
Pressure measurement experiment.
The pressure acting on the liquid inside the cavity was found using a polyvinyl difluoride (PVDF)-coated needle hydrophone (Dr. Müller Instruments, Oberursel, Germany). The needle gauge is inserted into the cavity at a distance of 3 mm from the foil surface (i.e., at the mouth of the 300-μm hole). The cavity was completely filled with the liquid (water), and metal foil was placed on top of the cavity. This arrangement was kept inside the device, and the metal foil was subjected to the micro-shock wave loading by igniting the explosive material inside the polymer tube. The pressure signals picked up by the needle gauge are recorded by the oscilloscope (Yokogawa Electric Corporation, Japan).
Bacterial strains used in this study.
Bacterial strains used in this study are described in Table S1 in the supplemental material.
Effect of micro-shock waves on the viability of bacteria.
Gram-negative (Salmonella enterica and Escherichia coli) and Gram-positive (Listeria monocytogenes) bacteria were used as models to study the effect of micro-shock waves on the bacteria. Cultures grown overnight were centrifuged, and the pellets were resuspended in sterile phosphate-buffered saline (PBS). The resuspended culture was loaded in the device, and after the explosion, the bacteria were delivered to the microcentrifuge tube. The cultures were serially diluted and plated on Salmonella-Shigella (SS) agar, LB agar, and brain heart infusion (BHI) medium for S. enterica, E. coli, and L. monocytogenes, respectively. An equal volume of untreated culture was plated as a control.
Delivery of bacteria using the device.
BALB/c mice were bred and housed at the Central Animal Facility at the Indian Institute of Science. The mice used for the experiments were 6 to 8 weeks old. All procedures with animals were carried out in accordance with the institution rules for animals. Hair on the skin was removed in the abdomen region using a hair clipper or commercial hair removal cream before the delivery of S. enterica serovar Typhimurium vaccine strain pmrG-HM-D (DV-STM-07) using the device. The delivery device was placed in a perpendicular position against the shaved abdominal skin of the mice, and the delivery of vaccine was carried out.
DV-STM-07 was administered to mice orally (107 CFU/mouse), intraperitoneally (i.p.) (104 CFU/mouse), and using the device (103 CFU/mouse) (5 mice in each group). DV-STM-07 was applied for 2 min to the skin of the appropriate controls (mice with hair removed) and then wiped using 70% ethanol to check the effect of hair removal. Mice were not fed for 12 h before oral infection. The mice were sacrificed after 3 days, and the liver, spleen, and mesenteric lymph nodes (MLN) were aseptically isolated, weighed, and homogenized in sterile PBS. The homogenate was plated in serial dilutions on SS agar to determine the bacterial load in various organs. The number of CFU was counted and shown as CFU/gram of organ.
Confocal microscopy.
Penetration of liquid jet into the polyacrylamide gel and skin of mice was confirmed using confocal laser scanning microscopy (LSM meta; Zeiss). Carboxylate-modified polystyrene fluorescent yellow-green latex beads (catalog no. L4655; Sigma-Aldrich) (4.6 × 109 particles per ml) and Salmonella Typhimurium expressing green fluorescent protein (GFP) were administered to mice using the device as described above. The skin was removed and mounted on a glass slide and immediately visualized using a confocal microscope. Images were obtained in xyz scanning mode and captured every 2 μm from the skin surface until no appreciable fluorescence could be detected.
Biofluorescence imaging.
Fluorescent yellow-green latex beads (catalog no. L4655; Sigma-Aldrich) with a size of 1 μm were taken at a concentration of 4.6 × 109 particles per ml and delivered to the dorsal side of mice using the device as mentioned above. The excitation passband (445 to 490 nm) and emission passband (515 to 575 nm) were set for GFP. Immediately after the delivery of fluorescent beads, mice were anesthetized with gaseous 5% isoflurane in O2 and imaged using a Xenogen IVIS 200 imaging system. The animals were placed in a ventral recumbent position and imaged from the dorsal aspect.
Immunization of mice.
DV-STM-07 was used as the vaccine strain in this study. The mice (6 mice per group) were immunized (103 CFU/mouse) using the device as described above with proper controls. PBS was given to mice by using the device as a control. Positive-control mice were vaccinated intraperitoneally (104 CFU/mouse). After 5 days, all mice were challenged orally with virulent Salmonella for organ burden (107 CFU/mouse) and for survival assay (108 CFU/mouse). Mice were observed twice a day for morbidity and mortality.
Estimation of serum immunoglobulin G (IgG).
Blood samples were collected from the ocular vein of each mouse. Serum samples were collected by centrifugation and stored at −80°C until use. All serum samples were diluted in PBS supplemented with 1% bovine serum albumin (BSA) prior to use in an enzyme-linked immunosorbent assay (ELISA). ELISA was performed as mentioned elsewhere with some modifications (5).
The serum IgG titer specifically for Salmonella lipopolysaccharide (LPS) was measured by an ELISA. LPS (250 ng/100 μl/well) in 0.02% trichloroacetic acid was used to coat the wells in the ELISA plate. The plates were incubated at 37°C for 2 h, and the wells were subsequently blocked for 1 h at room temperature with 3% BSA. One hundred microliters of diluted serum was added to each well, the plate was incubated for 1 h at 37°C, and the wells were washed. Horseradish peroxidase (HRP)-conjugated anti-IgG antibody (1:10,000 dilutions) was added to the wells, and the plate was incubated for 1 h at 37°C. After the wells were washed, 100 μl of tetramethylbenzidine solution was added to each well and incubated for 15 min. Fifty microliters of 1 N H2SO4 was added to stop the reaction, and the optical density (OD) was measured at 450 nm. The highest dilution at which the absorbance of the sample exceeds the background absorbance by 2 standard deviations was taken as the endpoint titer of the sera.
Statistical analysis.
The data were subjected to statistical analysis by applying Student's t test and Mann-Whitney U test using Graph Pad Prism 5 software, and a P value of <0.05 was considered significant. The mortality and survival data were analyzed using the log rank test. All the experiments were repeated at least three times to confirm the results.
RESULTS AND DISCUSSION
In the present study, the instantaneous release of a finite amount of chemical energy is used for generating controlled micro-shock waves in the laboratory. The method uses small amounts (∼18 mg/m) of explosive (high melting explosive [octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine] and traces of aluminum) uniformly coated on the inner wall of a polymer tube of arbitrary length. When the microexplosive is ignited from one end of the polymer tube, a detonation wave is generated inside the tube, and the products of microexplosion are allowed to emanate from the open end. The release of a finite amount of energy (equivalent to 0.168 mg of trinitrotoluene) from the open end of polymer tube invariably generates spherical micro-shock waves (Fig. 1A). The sequential images of micro-shock waves emanating from the open end of the polymer tube were captured by a time-resolved schlieren technique (15) using a high-speed camera (Fig. 1B; see the video in the supplemental material).
After the microexplosion, instead of allowing the energy to be dissipated in the open, a thin metal foil is used to transfer the impulse momentum to the liquid, which is in a cylindrical drug-holding chamber (Fig. 1C). A 300-μm-diameter hole at the bottom of this chamber in the absence of an external force acts like a valve owing to the surface tension of the liquid and does not allow the drug to exit the chamber. The polymer tube is positioned in the top of the chamber and just touches the surface of a thin (100-μm-thick) brass foil. When the metal foil is exposed to a high-pressure impulse, it deflects instantaneously, transferring all the momentum to the liquid underneath, thereby causing instantaneous compression of the liquid column, which drives the liquid through the discharge hole as a liquid jet. On the basis of this phenomenon, a novel needleless vaccine delivery device was developed (Fig. 1D). Enough safety precautions by way of miniature rubber gaskets have been incorporated in the device to ensure that the gaseous products of combustion do not leak through the drug-holding chamber. The velocity of the jet coming out of the discharge hole depends on the instantaneous pressure acting on the liquid column inside the cavity. The maximum pressure observed by the liquid inside the cavity was more than 6.0 × 106 Pa (Fig. 2A). High-speed flow visualization studies have shown that the liquid jet comes out at a very high velocity (>100 m/s) from the chamber and penetrates into the target material. This energy transfer mechanism was used to deliver the liquid jet and was tested in 4% agarose gels and 20% polyacrylamide gels (skin model [26]) for the penetration studies (Fig. 2B and C). In a 4% agarose gel, the penetration depth of the water was about 2 mm, whereas in a 20% polyacrylamide gel, the penetration depth of the fluorescent latex bead mix was about 60 μm. Initially, an agarose gel was used to check the penetration of the liquid jet. The polyacrylamide gel consist of a cross-linked polymer with a high tensile strength (26) and small pore size, whereas the agarose gel has a larger pore size and comparably less tensile strength (24). The penetration depth was higher in the agarose gel because of the mechanical properties of the gel. The polyacrylamide gel, which is being used as a skin model because of the matrix structure of the polymer and mechanical property (26), was used to check the efficiency of the device before starting in vivo studies.
Before using the needleless delivery device for vaccine delivery, it was necessary to check the effect of shock waves on the vaccine strain, since earlier studies have documented deleterious effects on bacteria (7) and rat brain (12) upon exposure to shock waves. Salmonella enterica serovar Typhimurium vaccine strain pmrG-HM-D (DV-STM-07), Escherichia coli (Gram-negative), and Listeria monocytogenes (Gram-positive) bacteria were used to test the effect of micro-shock waves. The pressure waves produced by the device for ultrashort duration (microseconds) had no effect on the viability of both Gram-negative and Gram-positive bacteria (Fig. 3A). The effectiveness of DV-STM-07 (D. Chakravortty and V. D. Negi, 22 August 2008, international patent application PCT/IN2008/000524) as a vaccine has been demonstrated previously (22, 23) and was used as the vaccine strain in our study. The delivery device was tested for its efficacy of vaccination in the mouse model. There were no macroscopically visible injuries like bleeding, edema, or any other local reactions at the site of vaccination on the skin, immediately after delivery and up to 10 days after vaccination. DV-STM-07 given through the device (103 CFU/mouse) reached the secondary lymphoid organs (spleen, liver, and mesenteric lymph nodes [MLN]) at levels comparable to those of other modes of vaccine delivery (Fig. 3B).
Fluorescent yellow-green latex beads of ∼1 μm in size were used as a model for bacteria and were delivered to the abdominal region of the mouse using the device. The presence of fluorescent beads in the skin was confirmed by confocal microscopy. The fluorescent beads (Fig. 3C) and Salmonella expressing green fluorescent protein (see Fig. S1 in the supplemental material) were found to penetrate the skin to a depth of up to 50 to 80 μm. This shows that the device can deliver the vaccine effectively into the epidermis and dermis region of the skin. Biofluorescence imaging was also carried out to confirm the presence of fluorescent beads in the mouse model (Fig. 3D). The overall results show that the device can be used for effective vaccine delivery. DV-STM-07 delivered with this device does not penetrate deeper than the skin but may be localized in the epidermis and dermis layer of the skin (3).
In order to determine the efficiency of our device in delivering the vaccine, we immunized the mice with DV-STM-07 (103 CFU/mouse) using the device and then challenged the mice with virulent Salmonella (107 CFU/mouse) orally after 5 days. Mice immunized by the intraperitoneal (i.p.) route (104 CFU/mouse) were used as a positive control, and the Salmonella burden in the secondary lymphoid organs (MLN, spleen, and liver) was evaluated 4 days after the challenge. In the immunized mice, there was a minimum of 100-fold reduction in the Salmonella load in the organ compared to the organs of placebo control mice (P < 0.0007) (Fig. 4A). Surprisingly, it was observed that mice vaccinated by using the device had a lower organ burden than the mice immunized i.p. Vaccination using our device showed better efficiency even with 10% of the dose given to the controls. In the survival assay, mice vaccinated using the device and mice vaccinated i.p. showed 100% survival upon challenge with virulent Salmonella (108 CFU/mouse), whereas all the unvaccinated mice died within 8 days after the challenge (P < 0.0001) (Fig. 4B). Additional controls were used to check the effect of hair removal in mice before vaccination. DV-STM-07 (104 CFU/mouse) was applied to skin after the removal of hair using a hair clipper or commercial hair removal cream. After challenge with virulent Salmonella, the bacterial burdens in different organs were assessed. These mice showed no significant difference from the mice in the control group in organ load and in the survival assay (data not shown). These results clearly demonstrate that vaccination using the new micro-shock wave-assisted device measures up to the traditional vaccination strategies in this efficacy of protection even at the reduced dose. Even though there is a significant difference in the bacterial loads of the group vaccinated by the i.p. route and the group vaccinated using the device in Fig. 4A, there is no difference in morbidity or body weight.
We measured antibody responses in serum samples using an enzyme-linked immunosorbent assay (ELISA). After a single immunization of mice with DV-STM-07 using the device (103 CFU/mouse), the serum immunoglobulin G (IgG) titer specific to Salmonella lipopolysaccharide (LPS) was measured after 5 days. The IgG endpoint titer was significantly higher than when the vaccine was given by the oral or i.p. route (P < 0.0033) (Fig. 4C). This shows that the reduced dose that can be given with our device can induce a significantly higher humoral response. This may due to the efficient antigen-presenting Langerhans cells present in the epidermal layer of the skin.
The delivery of vaccine at a penetration depth of less than 100 μm may not elicit pain (13, 18). The mice did not make a sound during vaccine administration with the device, whereas they made sounds during needle injections. This shows that the device can deliver vaccine in the epidermal layer of skin where there are no sensitive pain nerve endings. Therefore, vaccine administration using the device will not elicit any acute pain in mice.
Studies show that intradermal vaccination offers better protection than the other routes of immunization (9). The delivery of vaccines to the epidermal layer of the skin is a major challenge while using needle injections. Administering vaccine to the epidermal layer of skin can be done with high efficiency using our device. Delivering vaccines in close proximity to the epidermal layer may facilitate the antigen recognition and uptake process by Langerhans cells (19). Since intradermal injection of hepatitis B and rabies vaccines required only 10% of an intramuscular dose to elicit an equivalent antibody response and seroconversion rate (6), the dose of vaccine can be reduced by using our device. The cost of our needleless device will be $200, and the cost per shot will be 10 cents. As sensitive nerve endings are not present in the epidermal layer of skin, delivery of vaccine using our device will be safer than intradermal needle injection. Given that most of the vaccines commercially available are in liquid formulations, our device can be used to deliver those vaccines regardless of their particle size and chemical nature. Its potential use to deliver insulin has far-reaching consequences, because diabetics have to take insulin at least twice a day for the rest of their lives. For them, this device will be a welcome relief. Optimizing the size of the liquid drug-holding chamber to different doses, changing the size of the discharge hole as a function of the viscosity of the liquid drug, and exploring the possibility of integrating the present device with an endoscopic catheter are some of the issues that will be addressed in future studies.
Supplementary Material
ACKNOWLEDGMENTS
We thank Amit Lahiri, Namrata Ramachandran Iyer, Sangeeta Chakraborty, Ananthalakshmi TK, and Sandhya Amol Marathe for critical comments. We thank Minakshi Sen for the confocal microscopy. We also thank Murali and Anish for assistance in the work. We thank the Central Animal Facility at the Indian Institute of Science for providing us with the animals.
We thank the Indian Institute of Science, Bangalore, India, for the funds to purchase a high-speed camera. This work was supported by the grant Provision (2A) Tenth Plan (191/MCB) from the Indian Institute of Science, Bangalore, India, and grants from the Department of Biotechnology (DBT 197 and DBT 172) to D.C. Infrastructure support from ICMR (Center for Advanced Study in Molecular Medicine), DST (FIST), and UGC (special assistance) is acknowledged. U.S.A. received a fellowship from the UGC.
Footnotes
Supplemental material for this article may be found at http://cvi.asm.org/.
Published ahead of print on 9 February 2011.
REFERENCES
- 1. Alarcon J. B., Hartley A. W., Harvey N. G., Mikszta J. A. 2007. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol. 14:375–381 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Arora A., Prausnitz M. R., Mitragotri S. 2008. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 364:227–236 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Azzi L., El-Alfy M., Martel C., Labrie F. 2005. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J. Investig. Dermatol. 124:22–27 [DOI] [PubMed] [Google Scholar]
- 4. Chen D., et al. 2000. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 6:1187–1190 [DOI] [PubMed] [Google Scholar]
- 5. Chen D., et al. 1996. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900–1905 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Fadda G., et al. 1987. Efficacy of hepatitis B immunization with reduced intradermal doses. Eur. J. Epidemiol. 3:176–180 [DOI] [PubMed] [Google Scholar]
- 7. Gerdesmeyer L., et al. 2005. Antibacterial effects of extracorporeal shock waves. Ultrasound Med. Biol. 31:115–119 [DOI] [PubMed] [Google Scholar]
- 8. Griffith W. C. 1981. Shock waves. J. Fluid Mechanics 106:81–101 [Google Scholar]
- 9. Hunsaker B. D., Perino L. J. 2001. Efficacy of intradermal vaccination. Vet. Immunol. Immunopathol. 79:1–13 [DOI] [PubMed] [Google Scholar]
- 10. Ito K., Fukumoto Y., Shimokawa H. 2009. Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Tohoku J. Exp. Med. 219:1–9 [DOI] [PubMed] [Google Scholar]
- 11. Jagadeesh G. 2008. Industrial applications of shock waves. Proc. Inst. Mech. Eng. Part G. J. Aerospace Eng. 222:575–583 [Google Scholar]
- 12. Kato K., et al. 2007. Pressure-dependent effect of shock waves on rat brain: induction of neuronal apoptosis mediated by a caspase-dependent pathway. J. Neurosurg. 106:667–676 [DOI] [PubMed] [Google Scholar]
- 13. Kaushik S., et al. 2001. Lack of pain associated with microfabricated microneedles. Anesth. Analg. 92:502–504 [DOI] [PubMed] [Google Scholar]
- 14. Kermode M. 2004. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19:95–103 [DOI] [PubMed] [Google Scholar]
- 15. Kleine H., et al. 2005. High-speed time-resolved color schlieren visualization of shock wave phenomena. Shock Waves 14:333–341 [Google Scholar]
- 16. Lingeman J. E., McAteer J. A., Gnessin E., Evan A. P. 2009. Shock wave lithotripsy: advances in technology and technique. Nat. Rev. Urol. 6:660–670 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Lopez A. D., Mathers C. D., Ezzati M., Jamison D. T., Murray C. J. L. (ed.). 2006. Global burden of disease and risk factors. The World Bank, Washington, DC: [PubMed] [Google Scholar]
- 18. McAllister D. V., et al. 2003. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 100:13755–13760 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Merad M., Ginhoux F., Collin M. 2008. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8:935–947 [DOI] [PubMed] [Google Scholar]
- 20. Miller M. A., Pisani E. 1999. The cost of unsafe injections. Bull. World Health Organ. 77:808–811 [PMC free article] [PubMed] [Google Scholar]
- 21. Mitragotri S. 2005. Immunization without needles. Nat. Rev. Immunol. 5:905–916 [DOI] [PubMed] [Google Scholar]
- 22. Negi V. D., Nagarajan A. G., Chakravortty D. 2010. A safe vaccine (DV-STM-07) against Salmonella infection prevents abortion and confers protective immunity to the pregnant and new born mice. PLoS One 5:e9139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Negi V. D., Singhamahapatra S., Chakravortty D. 2007. Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model. Vaccine 25:5315–5323 [DOI] [PubMed] [Google Scholar]
- 24. Normand V., Lootens D. L., Amici E., Plucknett K. P., Aymard P. 2000. New insight into agarose gel mechanical properties. Biomacromolecules 1:730–738 [DOI] [PubMed] [Google Scholar]
- 25. Reid S. 2009. Increase in clinical prevalence of AIDS implies increase in unsafe medical injections. Int. J. STD AIDS 20:295–299 [DOI] [PubMed] [Google Scholar]
- 26. Schramm-Baxter J., Katrencik J., Mitragotri S. 2004. Jet injection into polyacrylamide gels: investigation of jet injection mechanics. J. Biomech. 37:1181–1188 [DOI] [PubMed] [Google Scholar]
- 27. Song J. M., et al. 2010. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin. Vaccine Immunol. 17:1381–1389 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Sullivan S. P., et al. 2010. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16:915–920 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. van der Jagt O. P., et al. 2009. Unfocused extracorporeal shock wave therapy as potential treatment for osteoporosis. J. Orthop. Res. 27:1528–1533 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.